Therefore, the blockage of TNF-α has been investigated as a therapeutic target in a clinical trial aimed at prolonging the endogenous release of insulin in pediatric patients newly diagnosed with T1D [123] (Table 2). This evidence concerns the gene TNF and type 1 diabetes mellitus.